<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03932864</url>
  </required_header>
  <id_info>
    <org_study_id>145-HV-101</org_study_id>
    <nct_id>NCT03932864</nct_id>
  </id_info>
  <brief_title>Study Assessing Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MGTA-145 in Healthy Volunteers as a Single Agent or in Combination With Plerixafor</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Ascending Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Parameters of MGTA-145 in Healthy Subjects Administered as a Single Agent, as Well as in Combination With Plerixafor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magenta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magenta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145
      in healthy volunteers as a single agent and in combination with plerixafor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of up to four parts: Part A, to investigate the safety and tolerability of
      MGTA-145; Part B, to investigate the safety and tolerability of MGTA-145 when administered in
      combination with plerixafor; Part C, to investigate the safety and tolerability of two
      sequential days of dosing MGTA-145 in combination with plerixafor; and Part D, to investigate
      the safety, tolerability, and measure by apheresis, the total number of CD34+ cells mobilized
      after a dose of MGTA-145 administered in combination with plerixafor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by incidence of treatment-emergent adverse events (AEs), serious adverse events (SAEs), and doselimiting toxicities (DLTs).</measure>
    <time_frame>28 days</time_frame>
    <description>Investigate the safety and tolerability of MGTA-145 following intravenous (IV) administration as monotherapy or in combination with plerixafor in healthy subjects (e.g. adverse events, clinical laboratory tests, vital signs, ECGs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate area under the curve (AUC) of MGTA-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate area under the curve (AUC) of MGTA-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate maximum plasma concentration (Cmax) of MGTA-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate clearance (CL) of MGTA-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate maximum plasma concentration (Cmax) of MGTS-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investiagte the volume of distribution at steady state (Vdss) of MGTA-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate the half-life of MGTA-145</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Assess CD34+ cells per uL of blood by flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Biomarkers</measure>
    <time_frame>15 days</time_frame>
    <description>Assess stem cell progenitors (colony forming units)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Single Ascending Dose of MTGA-145 or placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MGTA-145 or placebo dose escalation as single agent, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single Dose MGTA-145 or placebo plus plerixafor</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>MGTA-145 or placebo in combination with plerixafor, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose MGTA-145 plus plerixafor for 2 sequential d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-145 in combination with plerixafor on two consecutive days; single dose per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Single dose MGTA-145 plus plerixafor followed by apheresis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-145 in combination with plerixafor followed by apheresis</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGTA-145</intervention_name>
    <description>MGTA-145 will be given in various doses intravenously</description>
    <arm_group_label>Single Ascending Dose of MTGA-145 or placebo</arm_group_label>
    <arm_group_label>Single Dose MGTA-145 or placebo plus plerixafor</arm_group_label>
    <arm_group_label>Single dose MGTA-145 plus plerixafor followed by apheresis</arm_group_label>
    <arm_group_label>Single dose MGTA-145 plus plerixafor for 2 sequential d</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>plerixafor</intervention_name>
    <description>240 µg/kg subcutaneously</description>
    <arm_group_label>Single Dose MGTA-145 or placebo plus plerixafor</arm_group_label>
    <arm_group_label>Single dose MGTA-145 plus plerixafor followed by apheresis</arm_group_label>
    <arm_group_label>Single dose MGTA-145 plus plerixafor for 2 sequential d</arm_group_label>
    <other_name>Mozobil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be given in various doses intravenously</description>
    <arm_group_label>Single Ascending Dose of MTGA-145 or placebo</arm_group_label>
    <arm_group_label>Single Dose MGTA-145 or placebo plus plerixafor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18 to 60 years

          2. Body weight ≥50 kg and body mass index 19 to 33 kg/m2

          3. No clinically significant abnormalities on physical examination at Screening

          4. Non-smoker for at least 2 years

          5. No clinically significant lab abnormalities for renal, hepatic or hematologic
             parameters

          6. No clinically significant abnormalities on ECG

          7. Female subjects must be of non-childbearing potential

          8. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or
             those who are sexually active with a female partner(s) and agree to use an acceptable
             method of contraception

          9. No contraindications for apheresis

        Exclusion Criteria:

          1. Any clinically significant laboratory value outside the normal range at screening

          2. Donation of more than 500 mL of blood or plasma within 12 weeks prior to dosing

          3. History of alcoholism or drug abuse within the past 3 years

          4. Subject has used any prescription drugs within 14 days prior to dosing or any dietary
             supplements or non-prescription drugs within 7 days prior to dosing

          5. Acute illness, infection (requiring medical treatment [eg, antibiotics]), or surgery
             within 4 weeks of dosing

          6. Seropositive for hepatitis B surface antigen, hepatitis C virus antibody, or human
             immunodeficiency virus

          7. Subject has received another investigational drug or participated in an
             investigational drug or device study within 12 weeks prior to dosing

          8. History of anaphylaxis or clinically important reaction to any drug including
             plerixafor

          9. Any clinically significant hematologic, cardiovascular, pulmonary, central nervous
             system, metabolic, renal, hepatic, or gastrointestinal conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medpace CPU</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Plerixafor octahydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

